Meridian bioscience stock.

Feb 1, 2023 · Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms ... Meridian Bioscience has 5 employees across 11 locations and $333.02 m in annual revenue in FY 2022. See insights on Meridian Bioscience including office locations, competitors, ... Stock Price. $34. 2023-01-30. Market Capitalization. $1.5 B. 2023-01-30. Revenue. $333 M. FY, 2022.Popular SearchesMeridian Bioscience IncMERIDIAN BIOSCIENCE CorpMeridian BioscienceMeridian Life Science IncMeridian Life Science ... Meridian Bioscience's stock ...Meridian’s shares are traded on the NASDAQ Global Select Market, symbol VIVO. Meridian’s website address is www.meridianbioscience.com. Meridian Contact: Charlie Wood Vice President – Investor Relations Meridian Bioscience, Inc. Phone: +1 513.271.3700 Email: [email protected]

Meridian Bioscience ( NASDAQ: VIVO) is a fast-growing company in the medical device industry. It has demonstrated a strong profitability record of approximately 60% gross profit margin and 20% ...Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 33.33% and 2.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues …About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets and distributes a broad range of innovative diagnostic products.

Jan 30, 2023 · Get Meridian Bioscience Inc. (VIVO) share price today, stock analysis, price valuation, performance, fundamentals, market cap, shareholding, and financial report. Jan 31, 2023 · The estimated Net Worth of James M. Anderson is at least $1.07 Milion dollars as of 6 January 2023. Mr. Anderson owns over 8,500 units of Meridian Bioscience stock worth over $958,769 and over the last 14 years he sold VIVO stock worth over $0. In addition, he makes $114,667 as Independent Director at Meridian Bioscience.

Description. Fast qPCR Mix has been designed with a highly optimized buffer chemistry and hot-start DNA polymerase, to give highly sensitive qPCR efficiency, even from low abundance targets and scarce samples. With high processivity and robustness, it delivers excellent results in both singleplex and multiplex qPCR assays and confers superior ...May 3, 2019 · View %COMPANY_NAME% VIVO investment & stock information. Get the latest %COMPANY_NAME% VIVO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... Meridian Bioscience Inc ... Dec 13, 2022 · A high-level overview of Meridian Bioscience, Inc. (VIVO) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. To view our range of antigens and antibodies for immunoassay development please visit our partner site meridianlifescience.com

About Life Science. Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products and critical raw materials. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that redefine the ...

Diagnostics Solutions. Meridian Bioscience provides best-in-class diagnostic platforms, tests, education, and support to help you deliver answers. Which disease do you need to test for? Meet Revogene ®. Learn more about the innovative Revogene molecular platform.

Get the latest stock quote, charts, news and analysis for Meridian Bioscience, Inc. (VIVO), a medical equipment company that develops diagnostic tests for various conditions. See the company's performance, earnings, acquisitions, acquisitions, and more on MarketScreener. Feb 9, 2023 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the third quarter ended June 30, 2022.. Third …Meridian Bioscience hits 52-week high; stock up 36% YTD SA News Wed, Jun. 08, 2022 2 Comments. Meridian Biosciences says its qPCR mixes can be used in monkeypox molecular testsVIVO stock is in the headlines as the company discloses a financial update. Meridian Bioscience ( VIVO) agreed to be acquired by SD Biosensor and SJL Partners in a $1.53 billion deal. Also, the ...

Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before ...Meridian Bioscience has thrived during the COVID-19 pandemic. Can this stock go much higher, or is it time to cash out? Meridian Bioscience ( VIVO) ran past its 52-week high last week, closing on ...2 août 2022 ... ... stock starting 7 June. Meridian Bioscience develops, produces, markets, and distributes a range of diagnostic products in areas that include ...8 juil. 2022 ... ... Meridian Bioscience Inc. for about 2 trillion won (US$1.53 billion) in ... Korea suspends stock short selling until start of July 2024 · Most ...The stock of Meridian Bioscience (NAS:VIVO, 30-year Financials) shows every sign of being fairly valued, according to GuruFocus Value calculation.Find the latest stock market trends and activity today. Compare key indexes, including Nasdaq Composite, Nasdaq-100, Dow Jones Industrial & more.

Maksim Labkouski. Meridian Bioscience (NASDAQ:VIVO) rose 8% after it said its planned sale to SD Biosensor, SJL Partners, is expected to close on Jan. 31.Meridian and the buyer group agreed to ...CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has ...

8 Jul 2022 ... That represents a 32% premium to Meridian's closing stock price of ... “We are pleased to be a family with Meridian Bioscience as a great ...About Meridian Bioscience, Inc. Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.CINCINNATI, Nov. 28, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, has been awarded the distinguished ...Jun 24, 2020 · Meridian Bioscience has thrived during the COVID-19 pandemic. Can this stock go much higher, or is it time to cash out? Meridian Bioscience ( VIVO) ran past its 52-week high last week, closing on ... 22 nov. 2022 ... Analyze up to 10 years of full 10K Annual Reports and Quarterly 10Q SEC filings for Meridian Bioscience Inc (VIVO) using our online tools.Dec 1, 2023 · Susan D. Rolih is the Consultant at Meridian Bioscience. Markets; Tools Portfolios. Track performance, allocation, dividends, and risks. Search SEC filings. Annotate, download XLSX & look up similar tables. Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ...Meridian Bioscience is the IBD 50 Stocks To Watch pick for Wednesday as it eyes a new buy point and is forming a bullish base. It comes after VIVO stock ran as much as 456% above its 2020 lows. X ...Jan 30, 2023 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... Looking to buy Meridian Bioscience Stock? View today's VIVO stock price, trade commission-free, and discuss VIVO stock updates with the investor community.Meridian Bioscience is the IBD 50 Stocks To Watch pick for Wednesday as it eyes a new buy point and is forming a bullish base. It comes after VIVO stock ran as much as 456% above its 2020 lows. X ...

7 juil. 2022 ... Meridian shareholders will receive $34 per share in cash, a 1.3% premium to the stock's closing price on Wednesday, under the deal. The ...

12 déc. 2022 ... ... will revise the expected date of acquiring stocks and investment securities of Meridian Bioscience from Jan. 7 to Jan. 31, 2023."This is a.

Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...Jan 31, 2023 · Lourdes Weltzien owns over 20,000 units of Meridian Bioscience stock worth over $3,500,541 and over the last 5 years he sold VIVO stock worth over $0. In addition, he makes $675,550 as Executive Vice President - Life Science at Meridian Bioscience. Wallmine is a radically better financial terminal.Meridian Bioscience, Inc. (NasdaqGS:VIVO) agreed to acquire Exalenz Bioscience Ltd (TASE:EXEN) from Mori Arkin and others for approximately ILS 170 million on February 19, 2020. According to the agreement, an inverted triple merger will be carried out, where for each share of Exalenz, the buyer will pay ILS 6.1 per share in cash.8 juil. 2022 ... ... Meridian Bioscience Inc. for about 2 trillion won (US$1.53 billion) in ... Korea suspends stock short selling until start of July 2024 · Most ...Meridian Bioscience announced July 7 it's entered into a definitive merger agreement to be acquired by a pair of South Korean-based firms, SD Biosensor and SJL Partners, in a deal valued at $1.53 ...Diagnostics Solutions. Meridian Bioscience provides best-in-class diagnostic platforms, tests, education, and support to help you deliver answers. Which disease do you need to test for? Meet Revogene ®. Learn more about the innovative Revogene molecular platform.Dec 12, 2022 · CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO ), a leading global provider of diagnostic testing solutions and life science raw materials, announced that it has ... VIVO | Complete Vivo Collaboration Solutions Ltd. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ... In an all-cash transaction valued at approximately $1.53bn, a consortium led by bio-diagnostic company SD Biosensor, Inc. and investment firm SJL Partners LLC is to acquire global provider of diagnostic testing solutions and life science raw materials Meridian Bioscience, Inc. Under the terms of the definitive merger agreement, Meridian ...Feb 22, 2022 · Meridian Bioscience, Inc. is a life science company. The Company is engaged in the development, manufacture, sale and distribution of diagnostic testing systems and kits, primarily for certain gastrointestinal and respiratory infectious diseases, and elevated blood lead levels; and the manufacture and distribution of bulk antigens, antibodies, immunoassay blocking reagents, specialized ...

10 jan. 2018 ... Meridian Bioscience sued over stock drop, diligence in buying lead blood-test firm ... An untold number of children across America might want to ...Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) announces that effective today it will have completed the purchase of all the outstanding capital stock of the Bioline group of companies consisting of Bioline Ltd (UK), Bioline GmbH (Germany), Bioline (Aust) Pty Ltd (Australia), Bioline Reagents Ltd, and Bioline USA, Inc for $23.3 million in cash on hand.Jan 31, 2023 · The estimated Net Worth of Catherine Sazdanoff is at least $365 millier dollars as of 29 April 2016. Ms. Sazdanoff owns over 7,700 units of Meridian Bioscience stock worth over $261,569 and over the last 8 years she sold VIVO stock worth over $0. In addition, she makes $103,333 as Independent Director at Meridian Bioscience.Under the terms of the agreement, Meridian shareholders will receive $34.00 per share in cash, which represents a premium of approximately 32% over Meridian's closing stock price on the day before ...Instagram:https://instagram. wurk payrollqcom dividendxme holdingsvalue of copper in a penny Meridian Bioscience ( NASDAQ: VIVO) is a fast-growing company in the medical device industry. It has demonstrated a strong profitability record of approximately 60% gross profit margin and 20% ... how to get money off stocks on cash appuber competitors EX-99.1 Exhibit 99.1 For Immediate Release MERIDIAN BIOSCIENCE REPORTS RECORD SETTING FIRST QUARTER FISCAL 2021 OPERATING RESULTS AND RAISES FULL YEAR FISCAL 2021 GUIDANCE CINCINNATI, OHIO February 5, 2021 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial …Dec 1, 2023 · Interactive chart of historical net worth (market cap) for Meridian Bioscience Inc. (VIVO). VIVO was delisted after December 31, 2022 and its final net worth on that date was $1.489B . How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. nyse insp Jan 31, 2023 · John has made over 6 trades of the Meridian Bioscience stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of VIVO stock worth $37,950 on 25 February 2020.Jan 31, 2023 · The estimated Net Worth of John P. Kenny is at least $17.5 Million dollars as of 24 June 2022. Mr Kenny owns over 74,996 units of Meridian Bioscience stock worth over $11,093,515 and over the last 6 years he sold VIVO stock worth over $4,939,280. In addition, he makes $1,508,705 as Pres and CEO & Director at Meridian Bioscience.